In these times especially, but far from exclusively, security of supply remains one of the biggest challenges for pharmaceuticals manufacturers, writes Justin Eames, senior manager, APM Solution Consulting, Aspen Technology, in an Expert View.
In this context, many of them have an intense focus on reducing supply chain disruption, increasing capacity of batch production and reducing batch losses. Reducing lifecycle maintenance costs and CAPEX remain high on the agenda, too. Notwithstanding compliance and safety, manufacturing equipment availability is therefore a top priority.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze